Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting
Oslo, 3 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract from its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) is accepted for presentation at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy.Verrica’s presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and will highlight the antitumor activity of LTX-315 - by Verrica designated as VP-315 - as determined by